Silica-chitosan hybrid coating on Ti for controlled release of growth factors

Department of Materials Science and Engineering, Seoul National University, Seoul, Korea.
Journal of Materials Science Materials in Medicine (Impact Factor: 2.59). 12/2011; 22(12):2757-64. DOI: 10.1007/s10856-011-4458-5
Source: PubMed


A hybrid material composed of a silica xerogel and chitosan was coated on Ti for the delivery of growth-factors. Fibroblast growth factor (FGF) and green fluorescence protein were incorporated into the coatings for hard tissue engineering. Silica was chosen as a coating material because of its high surface area as well as its good bioactivity. Chitosan provides mechanical stability and contributes to the control of the release rate of the growth factors. When the chitosan composition was 30% or more, the hybrid coating was stable physically and mechanically. The release of the growth-factors, observed in phosphate buffer solution at 37°C, was strongly dependent on the coating material. The hybrid coating containing FGF showed significantly improved osteoblast cell responses compared to the pure xerogel coating with FGF or the hybrid coating without FGF. These results indicate that the hybrid coating is potentially very useful in enhancing the bioactivity of metallic implants by delivering growth-factors in a controlled manner.


Available from: Jun-Hyeog Jang, Jan 07, 2014
  • Source
    • "All samples were sterilized in an autoclave for 15 min at 121 C. Following the sterilization, the scaffolds were immersed in green fluorescent protein (GFP) or rhBMP-2 solution that had been fabricated using Escherichia coli (E. coli) [32] [43]. Immersed specimens were put into a vacuum desiccator connected to a rotary pump for 10 min, incubated overnight at room temperature (RT), washed with DPBS twice and dried. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Metals have been used as biostructural materials because of outstanding mechanical reliability. However, low bioactivity and high stiffness in biological environments have been major issues of metals, causing stress shielding effects or foreign body reactions after implantation. Therefore, in this study, densified porous titanium has been introduced to achieve comparable mechanical properties to hard tissues and bioactivity that promote a better interface between the implant and bone. Porous titanium scaffolds were successfully fabricated through dynamic freezing casting, and were densified, controlling the degree of densification by applied strain. During densification, structural integrity of porous titanium was well maintained without any mechanical deterioration, exhibiting good pore connectivity and large surface area. Densified porous titanium possesses two important features that have not been achieved by either dense titanium or porous titanium: 1) mechanical tunability of porous scaffolds through densification that allows scaffolds to be applied ranging from highly porous fillers to dense load-bearing implants and 2) improved bioactivity through bioactive coating that is capable of sustainable release through utilizing high surface area and pore connectivity with controllable tortuosity. This simple, but effective post-fabrication process of porous scaffolds has great potential to resolve unmet needs of biometals for biomedical applications.
    Biomaterials 10/2014; 37. DOI:10.1016/j.biomaterials.2014.10.027 · 8.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AbstractA new family of biodegradable amino acid‐based poly(ether ester amide)s (AA‐PEEAs) consisting of three building blocks [poly(ε‐caprolactone) (PCL), L‐phenylalanine (Phe), and aliphatic acid dichloride] were synthesized by a solution polycondensation. Using DMA as the solvent, these PCL‐containing Phe‐PEEA polymers were obtained with fair to very good yields with weight average molecular weight (M w ) ranging from 6.9 kg/mol to 31.0 kg/mol, depending on the original molecular weight of PCL. The chemical structures of the PCL‐containing Phe‐PEEA polymers were confirmed by IR and NMR spectra. These PCL‐containing Phe‐PEEAs had lower T g than most of the oligoethylene glycol (OEG) based AA‐PEEAs due to the more molecular flexibility of the PCL block in the backbones, but had higher T g than non‐amino acid based PEEA. The solubility of the PCL‐containing Phe‐PEEA polymers in a wide range of common organic solvents, such as THF and chloroform, was significantly improved when comparing with aliphatic diol based poly(ester amide)s and OEG based AA‐PEEAs. © 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2012
    Journal of Applied Polymer Science 07/2012; 125(1). DOI:10.1002/app.35536 · 1.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Due to the disadvantages of the current bone autograft and allograft in many clinical condition in which bone regeneration is required in large quantity, engineered biomaterials combined with growth factors, such as bone morphogenetic protein-2 (BMP-2), have been demonstrated to be an effective approach in bone tissue engineering, since they can act both as a scaffold and as a drug delivery system to promote bone repair and regeneration. Recent advantages in the field of engineered scaffolds have been obtained from the investigation of composite scaffolds designed by the combination of bioceramics, especially hydroxyapatite (HA), and biodegradable polymers, such as poly (D,L-lactide-co-glycolide) (PLGA) and chitosan, in order to realize osteoconductive structures that can mimic the natural properties of bone tissue. Herein it is demonstrated that the incorporation of BMP-2 into different composite scaffolds, by encapsulation, absorption or entrapment, could be advantageous in terms of osteoinduction for new bone tissue engineered scaffolds as drug delivery systems and some of them should be further analyzed to optimized the drug release for future therapeutic applications. New design concepts and fabrication techniques represent novel challenges for further investigations about the development of scaffolds as a drug delivery system for bone tissue regeneration.
    Clinical Cases in Mineral and Bone Metabolism 09/2013; 10(3):155-161.
Show more